Biologic Therapy for Osteoarthritis in Eugene, OR

Eugene epidemiology first — then the SKU

If a sales sheet cannot tell you that Eugene is JF (Noridian Healthcare Solutions) and that adult diabetes here is 9.4% (PLACES 2023), it is selling units, not a program. That is the osteoarthritis biologic therapy conversation we actually have.

If you already “have a vendor”

• Adult arthritis here is 26% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 8.3% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Oregon.
• Orthopedic and wound-care buyers in Oregon are often different people inside the same health system. A single Hawk Medical account can still require two utilization policies so 361 tissue and CTPs are not interchanged.
• Oregon is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).

City rate, state belt, federal LCD — keep the grains

Three grains, kept separate on purpose. City: Census 176,654 and CDC PLACES crude rates. State: Oregon Health Authority, Diabetes Belt not in the core list. Federal: 21 CFR 1271 and Noridian Healthcare Solutions LCDs. CDC PLACES (2023, crude) estimates 9.4% of adults in Eugene have diagnosed diabetes — 2.6 points below the U.S. 12% figure.

A practical checklist for Eugene